Regulator waives off clinical trials, clears Sanofi TB drug

India carries the highest burden of TB with about 2.69 mn cases in 2018. About 40% of the country’s population is estimated to have latent TB infection. The waiver granted to Sanofi’s rifapentine, which is sold under the brand Priftin, is in the public interest, with a restricted marketing licence to supply the drug only for the government-run national TB programme.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/32dNNMi
via IFTTT